Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cancer Therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7,043 result(s) found for: Cancer Therapy. Displaying page 348 of 353.
    «« First « Previous 344  345  346  347  348  349  350  351  352  Next» Last»»
    EudraCT Number: 2008-006035-12 Sponsor Protocol Number: SG035-0004 Start Date*: 2009-03-24
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A Phase 2 study of SGN-35 in treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL)
    Medical condition: Systemic anaplastic large cell lymphoma (ALCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10065864 Anaplastic large-cell lymphoma, primary systemic type LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) IT (Completed) FR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005920-34 Sponsor Protocol Number: Uni-Koeln-1014 Start Date*: 2011-10-14
    Sponsor Name:University of Cologne
    Full Title: HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET
    Medical condition: Hodgkin Lymphoma intermediate stage
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022229-13 Sponsor Protocol Number: MORAb-003-009 Start Date*: 2011-04-14
    Sponsor Name:Morphotek Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in combination with Carboplatin and Paclitaxel or Docetaxel Followed by Pemetrexed in Chemotherapy n...
    Medical condition: Stage IV adenocarcinoma of the lung
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025038 Lung adenocarcinoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003398-51 Sponsor Protocol Number: R-Pola-Glo Start Date*: 2023-03-05
    Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in...
    Medical condition: aggressive large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003169-82 Sponsor Protocol Number: rAd-IFN-MM-301 Start Date*: 2019-01-30
    Sponsor Name:Trizell Ltd
    Full Title: A Phase III, Open Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination wit...
    Medical condition: Malignant Pleural Mesothelioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059518 Pleural mesothelioma malignant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001165-21 Sponsor Protocol Number: CHDM201I12201 Start Date*: 2022-02-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) IT (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020454-34 Sponsor Protocol Number: 20090482 Start Date*: 2012-05-09
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Disease in Subjects with Newly Diagnosed Multiple Myeloma
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) ES (Completed) DE (Completed) HU (Completed) CZ (Completed) GB (Completed) PT (Completed) IE (Completed) IT (Completed) AT (Completed) BG (Completed) SK (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000074-19 Sponsor Protocol Number: GCP#03.01.020 Start Date*: 2014-10-24
    Sponsor Name:Gamida Cell Ltd
    Full Title: Full title of the trial: Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescents and Adult Patients with Hematologic...
    Medical condition: High risk haematological malignancies
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    17.0 100000004864 10025316 Lymphoma NOS LLT
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    17.0 100000004864 10009015 Chronic myeloid leukemia LLT
    17.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-000717-20 Sponsor Protocol Number: CD-TCR-002 Start Date*: 2019-10-09
    Sponsor Name:Medigene AG
    Full Title: Long-Term Follow-Up Clinical Trial of Subjects Treated with PRAME TCR modified T cells, MDG1011
    Medical condition: High Risk Myeloid and Lymphoid Neopolasms
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061240 Malignant lymphoid neoplasm PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    16.1 100000004851 10028229 Multiple myelomas HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028557 Myeloid leukemia, acute LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000341-39 Sponsor Protocol Number: RG_12-268 Start Date*: 2013-07-23
    Sponsor Name:University of Birmingham
    Full Title: A Phase Ib Study of Eltrombopag and Azacitidine in Patients with High Risk Myelodysplastic Syndromes and Related Disorders
    Medical condition: High-risk Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukaemia (CMML-2) and Acute Myeloid Leukaemia (AML) with less than 30% blasts.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-003187-22 Sponsor Protocol Number: Uni-Koeln-908 Start Date*: 2008-04-17
    Sponsor Name:University of Cologne
    Full Title: HD18 for advanced stages in Hodgkins Lymphoma
    Medical condition: Hodgkin´s lymphoma advanced stage
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004981-85 Sponsor Protocol Number: CD101.IV.3.08 Start Date*: 2020-04-06
    Sponsor Name:Cidara Therapeutics, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults...
    Medical condition: Invasive Fungal Diseases in Adults undergoing Allogeneic Blood and Marrow Transplantation (BMT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017528 Fungal infectious disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) NL (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005826-27 Sponsor Protocol Number: EAE-2020/MM0107 Start Date*: 2021-01-26
    Sponsor Name:Hellenic Society of Hematology (EAE)
    Full Title: A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in combination with Lenalidomide and Dexamethasone in patients w...
    Medical condition: newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015720-28 Sponsor Protocol Number: CCRG 09-003 Start Date*: 2009-12-18
    Sponsor Name:Antwerp University Hospital
    Full Title: Therapeutic efficacy of Wilms tumor gene (WT1) mRNA-electroporated autologous dendritic cell vaccination in patients with myeloid malignancies and multiple myeloma: a phase II trial.
    Medical condition: Therapeutic vaccination with dendritic cells loaded with wilms' tumor 1 protein in patients with myeloid malignancies and multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10046859 Vaccination LLT
    12.0 10024329 Leukemia LLT
    12.0 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004750-15 Sponsor Protocol Number: AIO-STS-0415 Start Date*: 2017-10-06
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A randomized phase II study of Durvalumab (MEDI4736) and Tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma.
    Medical condition: advanced or metastatic soft tissue sarcoma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041299 Soft tissue sarcomas HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004599-19 Sponsor Protocol Number: INTERFANT-06 Start Date*: 2005-11-24
    Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR INFANTS UNDER ONE YEAR WITH ACUTE LYMPHOBLASTIC OR BIPHENOTYPIC LEUKEMIA
    Medical condition: acute lymphoblastic leukemia (ALL) or biphenotypic leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) FR (Ongoing) DE (Completed) GB (Completed) AT (Completed) PT (Completed) DK (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000128-42 Sponsor Protocol Number: HIT-HGG-2007 Start Date*: 2009-03-19
    Sponsor Name:Martin-Luther-University Halle-Wittenberg
    Full Title: International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adole...
    Medical condition: 1st line therapy of newly diagnosed, previously untreated high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents ≥ 3 years and < 18 years
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002224 Anaplastic astrocytoma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030288 Oligodendroglioma malignant LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066254 Gliomatosis cerebri PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026659 Malignant oligodendroglioma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018340 Gliosarcoma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060971 Astrocytoma malignant PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017701 Ganglioglioma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003572 Astrocytoma malignant NOS LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008093 Cerebral astrocytoma, high grade LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004264-39 Sponsor Protocol Number: 26866138-MMY-2060 Start Date*: 2009-01-30
    Sponsor Name:Janssen-Cilag EMEA Medical Affairs
    Full Title: A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE® on Myeloma related Bone Disease
    Medical condition: Myeloma related bone disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DK (Completed) AT (Completed) GB (Completed) SE (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003645-42 Sponsor Protocol Number: CA209-140 Start Date*: 2014-02-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A single arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL) Revised protocol 03a, including amendment 04 and 05
    Medical condition: Lymphoma. Non-Hodgkin
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) ES (Prematurely Ended) IT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000089-45 Sponsor Protocol Number: OT-15-001 Start Date*: 2016-11-07
    Sponsor Name:Orbus Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur Af...
    Medical condition: Anaplastic Astrocytoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002224 Anaplastic astrocytoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) FR (Completed) IT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 344  345  346  347  348  349  350  351  352  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 14:44:59 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA